SCHEMBL27059362

SCHEMBL27059362

COC(=O)c1ccc(-c2nc(Nc3cnn(C4CCN(C(=O)OCc5ccccc5)CC4)c3)ncc2Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 13/20 0.53
▸ CDK1 P06493 1/20 0.53
▸ CDK2 P24941 1/20 0.53
▸ CDK8 P49336 1/20 0.53
▸ CDK7 P50613 1/20 0.53
▸ CDK9 P50750 1/20 0.53
▸ KCNH2 Q12809 1/20 0.53
▸ FLT4 P35916 3/20 0.45
▸ KDR P35968 2/20 0.45
▸ JAK2 O60674 1/20 0.43
▸ JAK1 P23458 1/20 0.43
▸ JAK3 P52333 1/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ MAP3K7 O43318 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ MAP2K1 Q02750 1/20 0.42
▸ GPR119 Q8TDV5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31557690 0.93 IGF1R (0.53) IGF1RCDK1CDK2CDK8CDK7
SCHEMBL27059360 0.93 IGF1R (0.53) IGF1RCDK1CDK2CDK8CDK7
SCHEMBL27059309 0.92 IGF1R (0.48) IGF1RCDK1CDK2CDK8CDK7
SCHEMBL22098023 0.91 IGF1R (0.48) IGF1RCDK1CDK2CDK8CDK7
SCHEMBL28606139 0.89 IGF1R (0.45) IGF1RCDK1CDK2CDK8CDK7
SCHEMBL22097740 0.86 IGF1R (0.52) IGF1RCDK1CDK2CDK8CDK7
SCHEMBL30956471 0.86 IGF1R (0.41) IGF1RCDK1CDK2CDK8CDK7
SCHEMBL29942050 0.86 IGF1R (0.47) IGF1RCDK1CDK2CDK8CDK7
SCHEMBL29249025 0.86 IGF1R (0.47) IGF1RCDK1CDK2CDK8CDK7
SCHEMBL24853389 0.86 IGF1R (0.52) IGF1RCDK1CDK2CDK8CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030870-B2 Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-07-09 — — US disclosed
US-20240025882-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030870-B2 Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof JAK2, JAK1, JAK3 IGF1R 2899/4885CDK1 146/4885CDK2 49/4885
US-20240025882-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF JAK2, JAK1, JAK3 IGF1R 2899/4885CDK1 146/4885CDK2 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback